IL4R - Wiki-MPM

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	ARIH2	ariadne RBR E3 ubiquitin protein ligase 2	Antigen processing: Ubiquitination & Proteasome degradation
Novel	CD40	CD40 molecule		Lucatumumab Dacetuzumab	Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency Hyper IgM syndromes, autosomal recessive type, including the following three diseases: Activation-induced cytidine deaminase (AICD) defect; Uracil nucleotide glycoside glycosylase (UNG) defect; Immunodeficiency with hyper-IgM type 3
Novel	DOK2	docking protein 2	Tie2 Signaling RET signaling
Novel	ERN2	endoplasmic reticulum to nucleus signaling 2
Novel	FES	FES proto-oncogene, tyrosine kinase	Signaling by SCF-KIT Sema3A PAK dependent Axon repulsion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion CRMPs in Sema3A signaling	Fostamatinib
Novel	HDGFL3	HDGF like 3
Novel	HGS	hepatocyte growth factor-regulated tyrosine kinase substrate	EGFR downregulation Lysosome Vesicle Biogenesis Ub-specific processing proteases Negative regulation of MET activity Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell RHOU GTPase cycle Endosomal Sorting Complex Required For Transport (ESCRT) Inhibition of membrane repair Prevention of phagosomal-lysosomal fusion RHOBTB3 ATPase cycle	Citric acid
Novel	IL13	interleukin 13	Interleukin-4 and Interleukin-13 signaling Interleukin-18 signaling	Cintredekin besudotox Lebrikizumab Lebrikizumab Dupilumab Tralokinumab Romilkimab	Graft-versus-host disease Asthma
Novel	IL13RA1	interleukin 13 receptor subunit alpha 1	Interleukin-4 and Interleukin-13 signaling
Novel	IL13RA2	interleukin 13 receptor subunit alpha 2	Interleukin-4 and Interleukin-13 signaling	AER001
Novel	IL2RG	interleukin 2 receptor subunit gamma	Interleukin-7 signaling Interleukin-7 signaling RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling Interleukin-15 signaling Interleukin-15 signaling Interleukin-9 signaling Interleukin-2 signaling Interleukin-21 signaling Interleukin receptor SHC signaling STAT3 nuclear events downstream of ALK signaling	Denileukin diftitox Aldesleukin Resatorvid	T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
Novel	IL4	interleukin 4	Interleukin-4 and Interleukin-13 signaling Interleukin-18 signaling	Pascolizumab Dupilumab Romilkimab	Asthma
Novel	INPP5D	inositol polyphosphate-5-phosphatase D	Synthesis of PIPs at the plasma membrane Synthesis of IP3 and IP4 in the cytosol Downstream TCR signaling PECAM1 interactions Interleukin receptor SHC signaling Signaling by CSF1 (M-CSF) in myeloid cells
Novel	IRS1	insulin receptor substrate 1	PI3K Cascade IRS-mediated signalling SOS-mediated signalling SOS-mediated signalling PIP3 activates AKT signaling Interleukin-7 signaling PI3K/AKT activation PI3K/AKT activation Signaling by ALK Constitutive Signaling by Aberrant PI3K in Cancer IRS-related events triggered by IGF1R Signaling by Leptin RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Activated NTRK3 signals through PI3K Signaling by ALK fusions and activated point mutants Growth hormone receptor signaling Signaling by LTK	[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
Novel	IRS2	insulin receptor substrate 2	PI3K Cascade IRS-mediated signalling SOS-mediated signalling SOS-mediated signalling PIP3 activates AKT signaling Interleukin-7 signaling PI3K/AKT activation PI3K/AKT activation Constitutive Signaling by Aberrant PI3K in Cancer IRS-related events triggered by IGF1R Signaling by Leptin RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation RET signaling Signaling by Erythropoietin Signaling by Erythropoietin Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phospholipase C gamma (PLCG) Erythropoietin activates STAT5 Erythropoietin activates RAS Erythropoietin activates RAS Growth hormone receptor signaling
Novel	JAK1	Janus kinase 1	Interleukin-6 signaling Interleukin-6 signaling MAPK3 (ERK1) activation MAPK1 (ERK2) activation ISG15 antiviral mechanism Interleukin-7 signaling Interleukin-7 signaling Other interleukin signaling RAF/MAP kinase cascade Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling IL-6-type cytokine receptor ligand interactions Interferon gamma signaling Regulation of IFNG signaling Regulation of IFNG signaling Interleukin-20 family signaling Interleukin-15 signaling Interleukin-15 signaling Interleukin-35 Signalling Interleukin-9 signaling Interleukin-2 signaling Interleukin-12 signaling Interleukin-12 signaling Interleukin-27 signaling Interleukin-27 signaling Interleukin-21 signaling Interferon alpha/beta signaling Interleukin receptor SHC signaling Regulation of IFNA/IFNB signaling Regulation of IFNA/IFNB signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Potential therapeutics for SARS Inactivation of CSF3 (G-CSF) signaling Inactivation of CSF3 (G-CSF) signaling SARS-CoV-2 activates/modulates innate and adaptive immune responses IFNG signaling activates MAPKs Evasion by RSV of host interferon responses PD-L1(CD274) glycosylation and translocation to plasma membrane	Myricetin 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one Ruxolitinib Tofacitinib Baricitinib Fostamatinib Fedratinib Filgotinib Abrocitinib Upadacitinib Pralsetinib Ivarmacitinib
Novel	JAK2	Janus kinase 2	Interleukin-6 signaling Interleukin-6 signaling MAPK3 (ERK1) activation MAPK1 (ERK2) activation Prolactin receptor signaling Prolactin receptor signaling Signaling by SCF-KIT Signaling by Leptin RMTs methylate histone arginines Interleukin-3, Interleukin-5 and GM-CSF signaling Interleukin-3, Interleukin-5 and GM-CSF signaling RAF activation RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling IL-6-type cytokine receptor ligand interactions Signaling by moderate kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Cyclin D associated events in G1 Interferon gamma signaling Regulation of IFNG signaling Regulation of IFNG signaling Interleukin-20 family signaling Interleukin-35 Signalling Signaling by Erythropoietin Signaling by Erythropoietin Interleukin-12 signaling Interleukin-12 signaling Interleukin-23 signaling Interleukin-23 signaling Interleukin-27 signaling Interleukin-27 signaling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phospholipase C gamma (PLCG) Erythropoietin activates STAT5 Erythropoietin activates RAS Erythropoietin activates RAS Interleukin receptor SHC signaling Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Potential therapeutics for SARS Inactivation of CSF3 (G-CSF) signaling Inactivation of CSF3 (G-CSF) signaling IFNG signaling activates MAPKs Growth hormone receptor signaling Growth hormone receptor signaling Factors involved in megakaryocyte development and platelet production	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one XL019 5-phenyl-1H-indazol-3-amine 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM Ruxolitinib Tofacitinib Pacritinib Baricitinib Entrectinib Fostamatinib Fedratinib Abrocitinib Zanubrutinib Pralsetinib	Polycythemia vera
Novel	JAK3	Janus kinase 3	Interleukin-7 signaling Interleukin-7 signaling Signaling by ALK RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling Interleukin-20 family signaling Interleukin-15 signaling Interleukin-15 signaling Interleukin-9 signaling Interleukin-2 signaling Interleukin-21 signaling Interleukin receptor SHC signaling Potential therapeutics for SARS	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one R-348 Ruxolitinib Tofacitinib Baricitinib Fostamatinib Abrocitinib Zanubrutinib	T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
Novel	NPIPB5	nuclear pore complex interacting protein family member B5
Novel	PRKCZ	protein kinase C zeta	GPVI-mediated activation cascade TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) VEGFR2 mediated cell proliferation RHO GTPases Activate NADPH Oxidases Estrogen-stimulated signaling through PRKCZ Estrogen-stimulated signaling through PRKCZ	Tamoxifen Staurosporine Dequalinium Benzoyl peroxide

Search Results for: IL4R